Regression to the clinical work, the combination of KIF14 knockdown and sorafenib treatment represents a promising therapeutic strategy for patients with HCC, especially for those sorafenib-tolerated [50]. The gene discussed is KIF14; the disease is hepatocellular carcinoma.